Background: The use of aripiprazole has been associated with a positive influence on mood and improved cognitive skills and social interactions; however, studies of its effects on young schizophrenic patients have been limited to active symptoms.
Aims: This prospective, open-label study investigated the neurocognitive effects of aripiprazole in adolescents and young adults with first and repeated episodes of schizophrenia.
Methods: Twenty-three of 42 schizophrenic outpatients aged 12-26 completed a trial of aripiprazole, and its efficacy was determined using the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impressions Severity (CGI-S) and WHO Quality of Life (WHOQOL) scales. Cognitive function was measured with the Cognitive Performance Test (CPT) and Wisconsin Card Sorting Test (WCST) at 4, 12 and 24 weeks of treatment.
Results: Results showed statistically significant improvements in BPRS, CGI-S and WHOQOL scores in certain (but not all) subcategories of cognitive measures including CPT detectability and total errors and perseverative errors on the WCST. There were few adverse side-effects.
Conclusions: Psychotic symptoms and cognitive skills improved during treatment with aripiprazole in adolescents and young adults with schizophrenia. Patients with first psychotic episodes did better than did those with repeat episodes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/08039488.2013.799228 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genomics yields biological and phenotypic insights into bipolar disorder.
Nature
January 2025
Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
Bipolar disorder is a leading contributor to the global burden of disease. Despite high heritability (60-80%), the majority of the underlying genetic determinants remain unknown. We analysed data from participants of European, East Asian, African American and Latino ancestries (n = 158,036 cases with bipolar disorder, 2.
View Article and Find Full Text PDF[Pharmacotherapeutic treatment in an adolescent with bipolar disorders].
Tijdschr Psychiatr
January 2025
Bipolar disorder (BD) frequently occurs in children and adolescents, but pharmacological treatment in this group presents significant challenges. Clinicians often struggle to find appropriate treatment guidelines due to the primary focus of current guidelines on adults, leaving specific recommendations for the acute and maintenance treatment of BD in children and adolescents either insufficient or entirely absent. This gap is partly due to the lack of targeted studies in this age group, leading practitioners to rely on clinical experience and studies conducted in adults.
View Article and Find Full Text PDFTreatment Analysis of Very Early and Early Onset Psychosis in the Youth Inpatient Setting.
HCA Healthc J Med
December 2024
St George's University, Grenada, West Indies.
Background: The United States Food and Drug Administration approved 6 atypical antipsychotics for pediatric treatment of schizophrenia. However, little has been published on the effectiveness of these medications in the acute treatment setting of adolescents with psychosis. Since the clinical uncertainty and poor prognosis proceeding the early onset of schizophrenia has a significant impact on a child's development, there is a critical need for evidence-based data on this population.
View Article and Find Full Text PDFTherapeutic Approach to Primary Tic Disorders and Associated Psychiatric Comorbidities.
Brain Sci
December 2024
Movement Disorder Unit, Neurology Department, Hospital de Sant Pau, 08041 Barcelona, Spain.
Background/objectives: The treatment of tics and psychiatric comorbidities is crucial when they affect the patient's well-being and relationships. However, the optimal pharmacological treatment (PT) tailored to each patient's phenotype remains unclear. The primary objective of this study is to describe the clinical characteristics and treatment received for tics and psychiatric comorbidities in our cohort of children and adult patients with tic disorders.
View Article and Find Full Text PDFLong-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder.
J Child Adolesc Psychopharmacol
January 2025
Director of Co-Founder and Founder of Schizophrenia Society, University of Cincinnati, Cincinnati, Ohio, USA.
Bipolar disorder often begins in adolescence or early adulthood, characterized by recurrent manic episodes that can lead to neurodegenerative brain changes and functional decline. While several oral second-generation antipsychotics are Food and Drug Administration (FDA)-approved for mania, adherence to maintenance treatment is frequently poor due to factors such as anosognosia, cognitive dysfunction, impulsivity, side effects aversion, and substance use. Long-acting injectable (LAI) antipsychotics, approved for adults with bipolar mania or schizoaffective disorder (bipolar type), offer a potential solution for adolescents with similar conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!